Bolni Marius Nagalo

Federal Grant PI

Associate Professor

UAMS

Last publication 2026 Last refreshed 2026-05-22

faculty

bolnimarius@gmail.com

17 h-index 101 pubs 1,142 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Bolni Marius Nagalo investigates mechanisms underlying diseases and potential therapeutic interventions. His recent work includes exploring the tumor microenvironment in pancreatic cancer as a therapeutic target and evaluating the synergistic effects of chemotherapy and CDK4/6 inhibitors in biliary tract cancers. Nagalo has also studied the role of fisetin in alleviating psoriasis-like skin inflammation by targeting mTOR/IL-17A and autophagy, and has synthesized pyrazole derivatives for potential anti-skin cancer, anti-tyrosinase, and antioxidant applications. Additionally, his research has examined the association between cell-free tumor DNA allele frequency and patient outcomes in advanced biliary cancers treated with platinum-based chemotherapy. Nagalo's scholarship metrics include an h-index of 18 and 90 total publications. He has served as a principal investigator on federal grants and collaborates with researchers at the University of Arkansas for Medical Sciences, including Steven R. Post, Mulu Z. Tesfay, Camila Simões, and Martin J. Cannon.

Metrics

h-index: 17
Publications: 101
Citations: 1,142

Selected Publications

Loss of FAM60A disrupts Sin3/HDAC control of the Hippo signaling and promotes oncogenic YAP1 activation (2026)

DOI OpenAlex
Prognostic factors and survival outcomes in colorectal cancer: insights from a Ghanaian cohort (2025)

DOI OpenAlex
The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer (2025)

1 citation DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

1 citation DOI OpenAlex
HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis (2025)

DOI OpenAlex
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)

DOI OpenAlex
Abstract 950: Engineered oncolytic vesiculovirus downsizes pancreatic tumor and boosts immune response (2025)

DOI OpenAlex
Abstract 2792: PiRNA as a novel therapeutic in hepatocellular carcinoma: insights from population screening (2025)

DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

DOI OpenAlex
Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059) (2025)

DOI OpenAlex
474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells (2025)

DOI OpenAlex
Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma (2025)

3 citations DOI OpenAlex
Association between extracellular matrix protein 1 (ECM1) gene polymorphisms(rs3834087 and rs3754217) and Hepatitis B Virus evolution in an African cohort (2025)

1 citation DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

4 citations DOI OpenAlex
Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled Release of Therapeutics (Adv. Mater. 45/2024) (2024)

DOI OpenAlex